Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Excess MicroRNA from Chromosome 21 Causes Down Syndrome Mental Impairment

By LabMedica International staff writers
Posted on 10 Apr 2013
Some of the neurological impairments typical of Down syndrome (DS) are caused by abnormally high levels of a microRNA (miRNA) that inhibits the manufacture of the protein SNX27 (sorting nexin 27).

DS, also known as trisomy 21, is a chromosomal condition caused by the presence of all or part of a third copy of chromosome 21. More...
It is the most common chromosome abnormality in humans and is typically associated with a delay in cognitive ability and physical growth and a particular set of facial characteristics.

SNX27 is a member of the sorting nexin family, a diverse group of cytoplasmic and membrane-associated proteins involved in endocytosis of plasma membrane receptors and protein trafficking through these compartments. All members of this protein family contain a phosphoinositide binding domain (PX domain). Mice that lack both genes for production of SNX27 have severe neuronal deficits in the hippocampus and cortex while mice with only one SBX27 gene have grossly normal neuroanatomy but have defects in synaptic function, learning, and memory.

Investigators at the Sanford-Burnham Medical Research Institute (La Jolla, CA, USA) analyzed brain tissue from subjects with DS and confirmed that they contained significantly lower levels of SNX27 than was found in normal individuals.

Studies carried out on a DS mouse model revealed that the activity of the SNX27 gene was being regulated by the microRNA miR-155, which is produced on chromosome 21. By having an extra copy of this chromosome an individual with DS generates excess miR-155, which results in abnormally low levels of SNX27 and mental defects.

Additional results published in the March 24, 2013, online edition of the journal Nature Medicine showed that a viral vector containing additional genes for SNX27 production could be inserted into the brains of the DS mice, and that return of SNX27 levels to normal corrected the animals' synaptic and cognitive deficits.

“In the brain, SNX27 keeps certain receptors on the cell surface - receptors that are necessary for neurons to fire properly,” said senior author Dr. Huaxi Xu, professor of neuroscience at the Sanford-Burnham Medical Research Institute. “So, in Down syndrome, we believe lack of SNX27 is at least partly to blame for developmental and cognitive defects.”

Related Links:

Sanford-Burnham Medical Research



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.